Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Obese HFpEF Patients (China)
CTR20211863Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF), obesity, sponsored by Eli Lilly and Company. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on CTR20211863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211863.